Latest Trading on NASDAQ

$75.23
2.09%
(+1.54)
Open 74.17
Previous Close 73.69
Today's Range
73.40 76.11
52 Week Range
32.95 76.11
Volume 312.25K
Avg. Volume (Weekly) 617.75K
Bid 75.18
Ask 75.27
Market Cap 4.25M
EPS -6.46
Shares Outstanding 57.65K
YTD High 76.11
Updated October 7, 2019

Arena Pharmaceuticals Inc.

Arena Pharmaceuticals Inc. (“Arena”) develops drugs that selectively target protein receptors of cells. Its research and development efforts are premised under the hypothesis that drugs designed to selectively target these receptors provide more effective and safe treatments.

No data to display.

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their first and only drug approved by any regulatory agency for marketing. BELVIQ was approved by the US Food and Drug Administration, or FDA, for marketing in the United States, and was made available by prescription in June 2013 to adults who are overweight with a comorbidity or obese. They are exploring BELVIQ for possible new indications, using different formulations, and in combination with other drugs.